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Evidence is accumulating that antibody dependent, cell-mediated cytotoxicity
(ADCC) plays a critical role in the mechanisms of defense against schistosomes
(1, 2) . In several experimental models and in the human situation, the partici-
pation of phagocytic cell populations, including macrophages, eosinophils, and
platelets, has been demonstrated (3-6). Killing in vitro of schistosomula, the
main targets of immune attack, is observed when these cells interact with the
parasite in the presence of specific antibodies (3, 5-9) .
During experimental rat schistosomiasis, or during human infection, large
variations in the cytotoxic activity of eosinophils attributable to immune com-
plexes may occur (7, 10), and it has been shown (10) that immune complexes
isolated from rat infection serum can either activate or inhibit schistosomulum
killing by normal eosinophils . More recently, the production of Schistosoma
mansoni-specific mAbs has allowed an alternative explanation for variations in
the capacity of different sera to support killing (11) . A rat IgG2cmAb (IPLSm3),
which did not exhibit any killing activity for schistosomula, specifically inhibited
the eosinophil-dependent cytotoxicity mediated by an IgG2a mAb (IPLSm 1)
(11) . The blocking effect of IgG2c was dual, both at the surface target antigen
(Mr 38,000) and at the effector cell level, by competition for the Fry receptor
(12, 13) . IgG2c antibodies were also able to inhibit the in vivo protection
conferred by IgG2amAbs .
The demonstration of such mechanisms in the rat raises the question of the
possible existence in human schistosomiasis of blocking antibodies modulating
the efficiency of immune effector mechanisms (14) . To test such a hypothesis,
we have studied a group of infected children who are involved in epidemiologic
and immunologic studies of schistosome infection (15, 16) . Among this group,
two subgroups have been distinguished . The first, one of 22 children showing
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high reinfection intensities (>I00 eggs per gram of feces), were considered to be
susceptible: the second, of 35 children who showed high levels of water contact
but low reinfection intensities (<30 eggs per gram of feces), were considered
resistant. Comparison of various parameters of the immune response in the two
subgroups, including antibody-mediated eosinophil-dependent killing of schisto-
somula, antischistosomulum IgE antibodies, and eosinophil levels measured as
an indirect estimate of eosinophil functional activity, showed no significant
differences (16) .
In the present work, we demonstrate the existence of blocking antibodies
capable of inhibiting eosinophil effector function in human infection with S.
mansoni, as previously shown for rat experimental schistosomiasis (11). A detailed
statistical study by Butterworth et al.' suggests that these blocking antibodies
may prevent the expression of immunity in young children.
Materials and Methods
Human Sera.
￿
Human sera were obtained from S. mansoni-infected patients before
and after treatment with oral oxamniquine (30 mg/kg). Subjects were living in an endemic
area in Kenya (Machakos district), which has already been described in previous papers
(15, 16). Normal human sera were prepared from S. mansoni-uninfected healthy donors.
All sera were stored in frozen aliquots at -70°C. When indicated, the sera were heated
for 2 h at 56'C.
Indirect Fluorescence Assay.
￿
Surface-binding antibodies were detected by indirect flu-
orescence on sections of S. mansoni schistosomula prepared as previously described (17).
The sections were overlaid either with total serum or fractions at various dilutions. After
a 30-min incubation and three washings in PBS, FITC-conjugated anti-human immuno-
globulin antisera at 1 :20 final dilutions were added (a, ju, or y chain-specific; Cappel
Laboratories, Cochranville, PA) for an additional 30 min. The slides were washed three
times in PBS and counterstained with Evans blue (1 :10,000 final dilution). Normal human
sera or medium were used as negative controls. The sections were examined under
fluorescence microscopy.
Serum Absorption.
￿
100 1.l of serum diluted (final dilution 1 :5) in MEM with penicillin
(100 U/ml) and streptomycin (100 ag/ml) were mixed in tubes with 100 mg protein A-
Sepharose (PAS)' (Pharmacia Fine Chemicals, Uppsala, Sweden) previously swollen and
equilibrated with medium . Tubes were loaded on a test tube rotator and agitated overnight
at 4°C. The unabsorbed fraction (PAS effluent fraction) was recovered by centrifugation
at 600 g for 10 min and tested as such in indirect fluorescence and cytotoxicity assays.
The bound IgG fraction was washed extensively and eluted with 0.5 ml 1 M glycine, pH
2 .8 (PAS eluate fraction) (18). The aliquots were immediately brought to neutral pH with
10 N NaOH dialyzed against PBS for 3 h and overnight against MEM.
Serum Fractionation (Ig Isotype Separation). A fast protein liquid chromatography
(FPLC) (Pharmacia Fine Chemicals) system was used for separation of IgM and IgG from
human sera (19). Briefly, after priming the gel filtration column (Superose 6) with PBS
(50 mM, pH 7.2), 100,ul of serum was filtered through a 0 .2-km filter and loaded onto
the column by a V-7 valve. The operating pressure was I millipascal, and the flow rate
was set at 0.5 ml/min. The fraction collector was programmed to collect 1-ml samples
(Fig. 1A). Ig isotype was determined by solid-phase RIA on plates coated with anti-human
immunoglobulin antisera specific for y or for )u chain (Cappel Laboratories) (Fig. 1 B).
' A. E. Butterworth, R. Bensted-Smith, A. Capron, M. Capron, P. R. Dalton, D. W. Dunne, J. M.
Grzych, H. C. Kariuki, J. Khalife, D. Koech, M. Mugambi, J. H . Ouma, T. K. arap Siongok, and R.
F. Sturrock. Immunity in human schistosomiasis mansoni. Prevention by blocking antibodies of the
expression of immunity in young children. Manuscript submitted for publication.
'Abbreviations used in this paper: FPLC, fast protein liquid chromatography; PAS, protein A-
Sepharose.1628
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￿
IgG and IgM separation from human sera by FPLC. (A) elution profile from the
chromatography column. (B) detection of IgM and IgG fractions by RIA. Plates coated with
anti-human IgM or anti-human IgG were incubated with 100 A1 of each fraction. After 2 h
of contact, wells were washed and then incubated with "5I-labeled anti-IgG or anti-IgM for 1
h at 37°C and overnight at 4°C.
Cytotoxicity Experiments. Sera were tested for their levels of heat-stable antibodies
mediating eosinophil-dependent damage to S. mansoni schistosomula according to methods
described elsewhere (16). Eosinophils were prepared from eosinophilic individuals by
centrifugation on discontinuous metrizamide gradients. Cell fractions collected from the
24-25% metrizamide layers were used in these assays. The experimental procedure for
the cytotoxicity assay was similar to that previously described (5). Briefly, 50 Y1 of the
schistosomula suspension (1,000 schistosomula/ml in MEM/NHS [heat-inactivated normal
serum]) were incubated either with 50 ul of heat-inactivated total human serum samples
or fractions at various dilutions. The effector cell suspension containing >90% eosinophils
at an E/T ratio of 5,000 :1 was then added. In some experiments, schistosomula were
preincubated with PAS effluents for 2 h at 37°C. After this incubation period, the
schistosomula targets were washed twice with medium before use in the cytotoxicity assay.
The percentage of cytotoxicity was evaluated after 48 h contact by microscopic exami-
nation .
Immunoprecipitation.
￿
Schistosomulum proteins were radioiodinated using the lactoper-
oxidase technique (20). Surface antigens were extracted by treatment of labeled parasites
with 0.5% NP-40 in Tris-HCI, pH 6.8, containing 100 U/ml aprotinin for 30 min at 0°C
(105 parasites per 0.5 ml), and immunoprecipitated with antibodies present in immune
sera as previously described (21) . Briefly, aliquots corresponding to 500 schistosomula
were incubated with 10 j1 of serum for 2 h at 4°C and then transferred into tubes
containing 10 mg of PAS previously swollen and equilibrated in adsorption buffer (5 mM
Tris-HCI, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2% Triton X-100, and 100 U/ml
aprotinin). PAS was sensitized with anti-human IgM before the addition of antigen-
antibody complex to identify the antigen recognized by IgM antibodies. In all experiments,
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tubes were agitated overnight at 4°C in a test tube rotator. The Sepharose beads were
then washed with 3 ml of 5 mM Tris-HCl, 0.15 M NaCl and 3 ml of 5 mM Tris-HCl, pH
7.4. Fixed complexes were eluted with 40 Fl of sample buffer (62.5 mM Tris-HCl, pH
6.8, 2% SDS, 10% sucrose, and 0.005% bromophenol blue) at 100°C for 3 min. The
eluted labeled antigens were identified by SDS-PAGE, and autoradiography was per-
formed according to the method described elsewhere (21).
Radioimmunoassay.
￿
Sera and Ig fractions (IgG, IgM) were tested for their capacity to
inhibit the binding to antigen of two rat mAbs against the 38,000 M, schistosomulum
surface antigen (11). Inhibition of binding of radiolabeled IgG2a (IPLSmI) and IgG2c
(IPLSm3) mAbs was performed according to the technique previously described (22).
Briefly, polyvinyl chloride (PVC) plates precoated with rat IgM (Cs-109) mAb recognizing
the 38,000 M, antigen were incubated with 100 yl of schistosomula NP-40 extract (1 mg/
ml). After a 2-h exposure at 37 0C, plates were washed twice in PBS/0.1 % BSA buffer.
For the inhibition test, 100 kt1 of sera or Ig fractions (1 :10 final dilution) were added.
After 2 h incubation at 37°C and three washings, plates were incubated with "'I-labeled
IgG2a or IgG2c for 1 h at 37°C, and overnight at 4° C, and the plates were then washed
three times.
The crossinhibition between the Ig fractions purified from human sera by FPLC system
was performed as described above. Wells precoated with schistosomulum NP-40 extract
were preincubated with unlabeled IgM or IgG fraction for 2 h at 37°C. After three
washings, plates were incubated with the homologous human ' 25I-IgG or -IgM fraction
(labeled by the chloramine T method; 1 ag/ACi) (23). After I h at 37 ° C and overnight at
4 °C, the plates were washed three times. In all experiments, the wells were counted in a
gamma counter. Percent inhibition of binding was calculated as [100 X (cpm without
inhibitor) - (cpm in the presence of inhibitor))/(cpm without inhibitor).
Determination of IgM Antibodies.
￿
A double-sandwich ELISA was used to detect IgM
antibodies against the 38,000 M, antigen (24). Microtiter plates coated with anti-human
IgM antibodies (Institut Pasteur Production, Marnes La Coquette, France) were washed
with saline/0.4% Tween and incubated for 3 h at room temperature with 200 Al of serum
diluted in PBS. After three washings, captured human IgM was incubated with 200 tcl
schistosomulum NP-40 extract (100 wg/ml) overnight at 4 ° C. The wells were then washed
with saline/Tween and incubated for 3 h at 4°C with 200 tl ofa galactosidase-conjugated
IgG2a mAb. Substrate containing 0 .014 M 2-nitrophenyl O-D-galactopyranoside (Merck,
Darmstadt, Federal Republic of Germany), 0.003 M MgCl2, and 0.1 M 2-ME (Sigma
Chemical Co., St. Louis, MO) was added to the test wells after a wash step, and the plates
were incubated for I h at 45 °C. The reaction was stopped by adding 500 juI of 1 M
Na2C03, and the absorbance was measured at 405 nm using a Titertek Multiskan (Flow
Laboratories, McLean, VA). Each test was assessed in duplicate. Results are expressed as
mean absorbance values at 405 nm.
Statistical Comparisons.
￿
The statistical significance ofdifferences between means were
analyzed by using Student's t test.
Results
Characterization of Antibodies Binding to Schistosomula.
￿
Intense membrane
fluorescence with FITC-anti-human IgG (Fig. 2A) or with FITC-anti-human
IgM (Fig. 2B) was observed after incubation of schistosomulum sections with
total serum from infected patients (n = 53 ; final dilution, 1:50) . Occasional and
weak fluorescence was seen with FITC-anti-human IgA (final dilution, 1 :5).
Identical fluorescence patterns persisted in the presence of the corresponding
IgG or IgM antibodies fractionated on PAS or FPLC system. No crossreaction
was observed between the purified fractions throughout the course of experi-
ments. Control sections incubated with human normal serum or with Ig fractions
purified from normal serum showed no reactivity either with FITC-anti-human
IgG or with FITC-anti-human IgM.1630
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FIGURE 2.
￿
Localization of the antigenic sites recognized by total serumand Ig fractions. (A)
indirect fluorescence on sections of S . mansoni schistosomula incubated with total serum and
revealed by FITC-anti-human IgG . (B) same asA using FITC-anti-human IgM .
Antibodies Mediating Eosinophil-dependent Killing of Schistosomulum .
￿
To deter-
mine the antibody isotype required in the cytotoxicity assay, 20 infected sera and
6 uninfected sera were fractionated either by absorption on PAS or by Ig
separation on chromatography column (FPLC system) . Each fraction was con-X
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FIGURE 3.
￿
Eosinophil-dependent killing of S. mansoni schistosomula by various fractions of
immune sera. The percentage of cytotoxicity was evaluated after 48 h of contact with
eosinophils. Sera or fractions obtained by PASor FPLC separation (1 :20, final dilution) were
heat inactivated for 2 h at 56°C. Open bars, immune serum; filled bars, normal serum (mean
of six experiments +SD).
trolled by indirect fluorescence assay and tested for their capacity to mediate
eosinophil-dependent killing of parasite larvae (Fig. 3). Detectable levels of
cytotoxicity were observed when S. mansoni schistosomula were incubated with
eosinophils purified from individuals with moderate eosinophilia in the presence
of heat-inactivated total immune sera. When the serum was fractionated, the
cytotoxic activity was detected in the IgG-containing fractions (PAS eluate
fraction or purified IgG fraction). Moreover, the IgG fractions produced signif-
icantly higher levels of cytotoxicity than the total sera, when tested in the same
conditions (p < 0.01). Apart from some direct toxicity (<5% ), no cytotoxic effect
was observed either in the presence of PAS effluent fractions or with IgM
fraction purified by FPLC . The control Ig fractions from normal serum did not
lead to any significant killing activity.
Inhibitory Activity ofIgM Antibodies.
￿
Since IgM antibodies were able to bind to
target surface, it was interesting to study their activity in eosinophil-dependent
cytotoxicity mediated by IgG antibodies . S. mansoni schistosomula were prein-
cubated with various dilutions of PAS effluents for 2 h at 37°C. After two
washings, total immune sera or PAS eluates and eosinophils were added. The
percentage of cytotoxicity was compared to the killing activity induced by total
immune serum or by PAS eluate fraction after preincubation of schistosomula
with medium. As shown in Table 1, preincubation of schistosomula with PAS
effluents of immune sera markedly inhibited the IgG-dependent cytotoxicity
mediated by total immune serum or PAS eluates in a dose-dependent manner (p
< 0.01). To rule out a possible nonspecific inhibition, schistosomula were
preincubated with PAS effluents of normal serum. Results presented in Table I
showed no inhibitory effect after the addition of total immune serum. Preincu-1632 IgM BLOCKING ANTIBODIES IN HUMAN SCHISTOSOMIASIS
TABLE I
Inhibitory Role ofIgM-containing PAS Effluents on IgG-dependent Cytotoxicity
by Human Eosinophils
Schistosomula were preincubated for 2 h at 37 °Candwashed twicewith medium. Thehomologous
serum or fractions were then added. Percent cytotoxicity was measured after 48 h contact with
eosinophils (mean ± SD of sevenexperiments).
* PASeffluent represents the unbound fraction to PAS.
$ PAS eluate represents thebound fraction to PASeluted with glycine (1 M).
$ Eosinophils were preincubated with PAS effluent and then washed with medium.
bation of eosinophils instead of target incubation with PAS effluents ofimmune
serum did not affect the killing activity oftotal immune serum.
Antibody Response to Schistosomula Surface Antigens.
￿
The target specificity of
IgG and IgM antibodies was determined. Immunoprecipitation of "'I-labeled
schistosomulum antigens from infected human serum using protein A-binding
antibodies (IgG antibodies) revealed 30,000-40,000 Mr antigens (100% of sera
tested; n = 17) (Fig. 4). However, additional bands in the 20,000-25,000 M,
range were revealed (66% of sera tested). Occasional faint bands were also
detected in the upper region of the gel (>67,000) (41% of sera tested). Surface
antigens precipitated by IgM antibodies from infected human serum ranged
from 30,000 to 40,000 Mr (100% of sera tested) and also between 20,000 and
25,000 M, (20% of sera tested). However, the predominant IgM antibody
response was against the 32,000 Mr antigen. Adsorption experiments, in which
the detergent extract was previously adsorbed by protein A-binding IgG anti-
bodies demonstrated a crossinhibition at the level of the whole antigen between
IgG and IgM antibodies (Fig. 4, lane 5) .
Epitopes Recognized by IgG and IgM Antibodies.
￿
To investigate the respective
epitopes recognized by IgG and IgM antibodies, we used an RIA in which the
capacity of IgG and IgM fractions to inhibit antigen binding of two rat mAbs
(IgG2a and IgG2c) was tested. These mAbs (IPLSml and IPLSm3) recognize
the 38,000 M, antigen. This antigen wasbound to plates by the use ofa different
rat mAb (C3-109) that does not interfere with the binding ofeither IPLSml or
IPLSm3. Preincubation of wells precoated with schistosomulum antigen in the
presence of IgG or IgM fractions of infected serum inhibited both the binding
of "'I-labeled IgG2a and IgG2c (Table II). In the same conditions, total serum
led to an twofold inhibition, when compared with the inhibition induced either
by the IgG or by the IgM fractions. The specificity of the epitopes recognized
by IgG and IgM antibodies in infected serum was tested by crossinhibition
Preincubation
(2 h at 37°C)
Incubation
(final dilution)
Percent
cytotoxicity
Medium Totalnormal serum 2.7 ± 0.0
Medium Total immune serum (1 :20) 36.5 ± 10.0
Medium PASeffluent* immune serum (1 :20) 4.9 ± 0.6
Medium PASeluate$ immune serum (1 :20) 45.5 ± 9.9
PASeffluent immune serum (1 :10) Total immune serum (1 :20) 8.2 ± 3.9
PASeffluent immune serum (1 :30) Total immune serum(1 :20) 20.4 ± 4.6
PASeffluent immune serum (1 :10) PAS eluate immune serum (1 :20) 11 .1 ± 1.5
PAS effluent normal serum (1 :10) Total immune serum(1 :20) 30 ± 5.2
PAS effluent immune serum (1 :10)1 Total immune serum(1 :20) 35.7 ± 6.5KHALIFE ET AL .
FIGURE 4 .
￿
Immunoprecipitation ofschistosomulum surface antigens by immune sera. Deter-
gent extracts of 500 labeled skin schistosomula were incubated with 10 kl of total serum or
100,u1 of PAS effluent fraction . Immune complexes of total serum were absorbed on PASand
wereanalyzed, in lanes 1 and3 . ProteinA-unbound material from lane 3was furtherincubated
with PAS effluent fraction, and immune complexes were analyzed in lane 5 . The immune
complexes ofPAS effluent fraction were absorbed on PAS previously sensitized with 10 P1 (1
mg/ml) of anti-human IgM (lanes 2, 4, and 5) .
TABLE 11
Inhibition ofBinding to Schistosomulum Antigen ofTwo Rat mAbs
Directed against the 38,000M, Antigen
Plates precoated with antigenwere preincubated with IgG, IgM fraction,
or total serum from infected patients (1 :10 final dilution) for 2 h at
37°C. Percent inhibition was calculated as described in Materials and
Methods (mean ± SD) . Inhibition by Ig fraction of normal serum or
total normal serumhas been subtracted.
* Purified anti-S. mansoni IgG2aand IgG2c mAbs were labeled by ' 251 by
the chloramine T method .
Number of sera tested .
§IgG and IgM fractions were obtained from total serum by fractionation
with an FPLC system .
1633
Preincubation
Labeled
Percent
IgG2a*
inhibition
Labeled IgG2c*
IgG fraction§ 30 ± 2.0 38 ± 5.7 17
IgM fractions 23 ± 1 .9 33 ± 3.7 17
Totalserum 55.8 ± 2.9 54.6 ± 4.1 171634
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FIGURE 5.
￿
Crossinhibition of binding to antigen of IgG and IgM fractions from immune
sera. Schistosomulum antigen boundto plates by using a ratmAb (C3-109) were preincubated
with IgG fraction (A) or with IgM fraction (B). After 2 h of contact and three washes,
homologous labeled IgM or IgG were added to A andB, respectively, and incubated for 1 h
at 37°C and overnight at 4°C. Results are presented as percent inhibition (see Material and
Methods) (mean of duplicate ±SD). Dots represent the inhibition between the Ig fractions of
immune sera; stars represent the inhibition of Ig fractions of infected sera by Ig fractions of
normal sera.
experiments. As shown in Fig. 5A, the preincubation ofantigen-coated plates in
the presence of IgG fraction inhibited the binding of homologous 125I-labeled
IgM antibodies. In the same conditions, higher levels of inhibition were obtained
when unlabeled IgM antibodies were preincubated before labeled IgG (Fig. 5B),
suggesting higher avidity for the targets.
Role of These IgM Antibodies in Immunity to Reinfection.
￿
The biological rele-
vance of such IgM blocking antibodies was assessed by the evaluation of anti-
38,000 IgM antibodies in the sera from individuals classified as resistant or
susceptible to reinfection using previously defined criteria (16). Such antibodies
were measured in an IgM capture assay (see Materials and Methods) in order to
avoidcompetition with the IgGantibodies. Resultspresented in Table III showed
that themean levels ofIgM antibodies in susceptible individuals were significantly
higher than those present in resistant subjects in the pretreatment and 12-mo
serum samples, but did not differ significantly at 5 wk after treatment. For the
susceptible population (defined previously [16] as those individuals having >100
eggs per gram of feces) there was a positive association between the level of IgM
antibodies in the pretreatment blood sample and the number of eggs at 12 mo
after treatment. In addition, there was a positive association at any given time
between IgM antibody levels and the actual egg counts at that time.
The numerous studies concerning the effector mechanisms directed against S.
mansoni schistosomula have shown that eosinophils can act as killer cells in the
presence of specific antibodies (1, 2). The factors directly involved in suchKHALIFE ET AL.
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TABLE III
Relationship between Presence ofIgM Antibodies against the 38,000 Schistosomulum Surface
Antigen and Status ofImmunity to Reinfection
Sera were selected from susceptible andresistantindividuals usingpreviously defined criteria. IgM
antibodies were measured by a capture assay (see Materialsand Methods). Preliminary studies, in
which varying concentrations of the serum (1 :100-1 :12,800) were used, indicated that a final
dilution of 1:6,400 wouldbe thehighest dilution to which the normal andimmune serum showed
a significant difference. Results are presentedas mean ± SEM. Number of sera used is shown in
parentheses. Egg counts were calculated by examination of duplicateKato preparations (geometric
mean).
* p < 0.01 between the two groups.
$p > 0.05 between the two groups.
§p < 0.001 between the two groups.
mechanisms include IgG and IgE antibodies (5, 7). However, in previous epide-
miological studies (16) ofhuman immunity to schistosome infection, comparison
of the levels of IgG and IgE antischistosomulum antibodies between two groups
classified as resistant and and susceptible to reinfection, respectively, showed no
significant difference. The demonstration in experimental models that defined
antibody isotypes might block the expression of immunity prompted us to
investigate the presence of such blocking antibodies leading to prevention of a
given effector mechanism during human schistosomiasis.
Evidence from fluorescence studies on schistosomulum sections indicated the
presence of IgG and IgM antibodies specifically directed against the schistoso-
mulum surface in sera from infected patients. As previously reported (7), in vitro
studies of the effector function of heat-inactivated immune serum revealed
significant levels of eosinophil-dependent cytotoxicity against S. mansoni schisto-
somula. In the same conditions, when serum samples were fractionated and
tested for their killing capacity, it was found that the activity was associated with
IgG antibodies eluted from protein A, whereas no cytotoxic activity was detected
in the PAS effluent preparation of IgM antibodies. Comparable results have
been obtained with IgG and IgM antibodies fractionated by FPLC. Moreover,
the IgG fraction produced significantly higher levels of cytotoxicity than total
immune serum. These results confirm a previous report (7) in which the authors
demonstrated the involvement of IgG antibodies. They suggest, in addition, that
the depletion of some inhibitory factor not retained on protein A led to an
increase in IgG-mediated killing.
The experiments showing that IgM-containing fractionswere unable to exhibit
any antiparasite killing activity in the presence ofeosinophils, together with the
demonstration (11) of blocking antibodies in rat experimental schistosomiasis,
Blood sample Before treatment
After
5 wk
treatment
12mo
Susceptible
Optical density 1.5 ± 0.09* (19) 0.97 ± 0.121 (21) 1.38 ± 0.11§ (21)
eggs per gram 206 7 133
Resistant
Optical density 1.19 ± 0.1* (34) 0.72 ± 0. It (24) 0.77 ± 0.07§ (32)
eggs per gram 110 0 81636
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led us to investigate the possible inhibitory role of IgM antibodies in eosinophil-
dependent cytotoxicity mediated by IgG antibodies. Preincubation of schistoso-
mula with PAS effluents or IgM-containing fractions of immune serum strongly
inhibited the cytotoxicity mediated by total immune serum or PAS eluate
fractions (IgG antibodies). The absence of inhibition with IgM purified from
normal serum confirmed that the blocking effect was related to the antiparasite
antibody specificity of IgM. In contrast, these IgM antibodies were unable to
inhibitthe killing capacity dependent upon specific IgEanti-S. mansoni antibodies
and eosinophils (data not shown). The interpretation of these observations is that
IgM blocking antibodies were crossreactive with the same target antigen as IgG
antibodies, and that IgE antibodies were directed against another antigen, as
previously described in rat schistosomiasis (25). In this context, previous studies
(26) reported in human schistosomiasis showed the presence of blocking antibod-
ies of IgG isotypes able to inhibit the histamine release induced by IgE-sensitized
basophils. It was interesting to note that several investigations (27, 28) have
demonstrated the presence of such blocking antibodies (IgG and IgA isotypes)
in malignant diseases. More recently, in rat experimental schistosomiasis, it was
shown (11, 12) that blocking antibodies (IgG2c) inhibited the IgG2a-dependent
eosinophil activation and cytotoxicity at the level both of the target antigen and
of the eosinophil Fc receptor. The present data showed that the preincubation
of eosinophils with blocking IgM antibodies did not inhibit the cytotoxic effect
of IgG antibodies, suggesting no crossinhibition between IgG and IgM antibodies
at the Fc receptor level.
This consideration prompted us to examine the antigens recognized by IgG
and IgM antibodies. The predominant surface antigens precipitated by protein
A-binding IgG and by IgM antibodies in infected human sera ranged between
30,000 and 40,000 Mr, with additional major bands at 20,000-25,000 Mr. The
antigens precipitated by the IgM antibodies could be removed by prioradsorption
with protein A-binding IgG antibodies. In addition, competition between IgM
and IgG antibodies to one of the major antigens, of 38,000 Mr, could be directly
demonstrated. The 32,000-38,000 M complex represents a cluster of related
antigens (29) and the preferential binding of IgM to the 32,000 A antigen, in
comparison with IgG, suggested the recognition of a nonidentical family of
epitopes on the 32,000-38,000 Mr complex.
To identify in more detail some of the epitopes recognized by IgG and IgM
antibodies, respectively, we used two previously-described rat mAbs, IPLSml (a
protective IgG2a antibody), and IPLSm3 (a blocking IgG2c antibody). Both of
these antibodies recognize carbohydrate epitopes on the 38,000 Amajor surface
antigen, and show crossinhibition of binding. In addition, the IPLSm3 mAb that
recognizes the 32,000 and 20,000 M, molecules (11), suggesting either that they
recognize structurally-related but not identical epitopes on the 38,000 M mole-
cule, or that they compete sterically. The binding of both IPLSml and IPLSm3
to the 38,000 M molecule could be inhibited by both IgG and IgM fractions of
human infected sera .
These findings indicate that the families of IgM and IgG antibodies in human
infected sera that have specificity to schistosomulum surface antigens include
antibodies with specificity to the major 38,000 Mr antigen. Such antibodies mayKHALIFE ET AL.
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compete with each other, either by direct competition for the same or structur-
ally-related epitopes, or by a steric inhibition ofbinding.
Our results revealed the existence, among the various antibodies specifically
directed against schistosomula surface in infected human sera, oftwo particularly
interesting antibodies. The first was of IgG isotype, and was able to induce the
killing of S. mansoni schistosomula in the presence of human eosinophils; the
second was of IgM isotype, and showed no cytotoxic effect, but demonstrated
an effective inhibition of eosinophil-dependent cytotoxicity mediated by IgG
antibodies. In the context ofthe in vivo relevance ofsuch findings we wanted to
know whether the presence of IgM antibodies could be used as a marker of
reinfection intensities to S. mansoni. We performed a capture assay to measure,
in human infected sera, the presence of IgM antibodies specific of the epitope
present on the 38,000 M,.antigen, asevaluated by using a second arm with IgG2a
mAbs. Results revealed that the mean level of IgM antibodies in individuals
classified as susceptible were significantly higher than those present in the
resistant individuals; there was a positive association between the level of IgM
antibodies in the pretreatment and the number ofeggs counted in the susceptible
group at 12 mo after treatment, suggesting that such IgM might be related to
subsequent reinfection. The positive association between IgM levels and egg
counts at any given time suggested, first, that these IgM antibodies may be
associated with antiegg responses, and second, that they fluctuate rapidly with
time (16). These results suggest that the production of blocking IgM antibodies
could be induced by the same epitope expressed on schistosomula and eggs.
Further statistical analysis (Butterworth et al.)' supported this hypothesis.
In conclusion, although our evidence is derived from in vitro studies, these
findings indicate that susceptibility to reinfection after treatment ofS. mansoni
infections in man might be explained in part by the presence of schistosomulum-
specific IgM blocking antibodies. In addition, they suggest indirectly a major
role played by the effector IgG antibodies directedagainst theM, 38,000 antigen.
The fact that theseantibodies are a necessary butnot limiting factor in immunity,
and the presence of blocking antibodies support the hypothesis that the acquisi-
tion of immunity might reflect the loss of a blocking response, rather than the
acquisition of an effector response. However, besides IgM antibodies, statistical
studies (Butterworth et al.)' raise the possibility that another antibody isotype
may block the protective response. The availability of this type of information
would be of considerable importance in defining the nature ofa vaccine capable
of inducing the production of both effector and blocking antibodies. However,
another approach to explain the prevention of immunity may involve idiotypic
regulation, whereby the protective antibodies may be blocked by antibodies
directed against the antigen-specific combining sites of effector antibodies (i.e.,
antiidiotype antibodies). Experiments are now under way to test this hypothesis.
Summary
After the demonstration of blocking antibodies during rat experimental schis-
tosomiasis, the existence of such factors was investigated in human schistosomi-
asis. The depletion, in sera from S. mansoni-infected pateints, of a given isotype
(IgM) either by protein A-Sepharose (PAS) absorption or by fast protein liquid163 8
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chromatography (FPLC) induced a significant increase in IgG-mediated killing
of S. mansoni schistosomula by human eosinophils. Inhibition experiments
showed that IgM-enriched fractions (PAS effluents) were able to inhibit eosino-
phil-dependent cytotoxicity mediated by IgG fractions (total sera or PAS eluates).
Both IgG and IgM antibodies from infected human sera immunoprecipitated
antigens of 30,000-40,000 Mr in the labeled detergent extracts of schistosomu-
lum surface. The specificity of IgG and IgM for the 38,000 Mr antigen was
suggested by competition experiments using two radiolabeled mAbs (IPLSmI,
IPLSm3) directed against this antigen . Moreover, crossinhibition between IgG
and IgM antibodies for the Mr 38,000 antigen could be directly demonstrated.
The in vivo relevance of such IgM blocking antibodies in the context of human
immunity to schistosomiasis was evaluated in two groups of children classified as
resistant or susceptible to posttreatment reinfection. IgM antibodies specifically
directed against the 38,000 Mr antigen were measured by a capture assay. The
mean levels of IgM antibodies were significantly higher in the susceptible than
in the resistant group both before and after treatment. These results are
consistent with the idea that immunity to schistosomiasis could be attributable
not only to the existence of antibodies with defined effector function, but also
to the absence of blocking antibodies. The description of the existence in human
schistosomiasis ofantibody isotypes blocking the effector response against defined
surface targets might lead to a new understanding of the mechanisms regulating
immunity to reinfection against schistosomes and possibly other parasites.
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